CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma
James L. Rubenstein,Valerie S. Wong,Cigall Kadoch,Hua Xin Gao,Ramon F. Barajas,Lingjing Chen,S. Andrew Josephson,Brian J. Scott,Vanja C. Douglas,Mekhala Maiti,Lawrence D. Kaplan,Patrick A. Treseler,Soonmee Cha,Jimmy Hwang,Paola Cinque,Jason G. Cyster,Clifford A. Lowell +16 more
Reads0
Chats0
TLDR
It is demonstrated for the first time that elevated CXCL13 concentration in cerebrospinal fluid (CSF) is prognostic and that CXC chemokine ligand and IL-10 mediate chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.About:
This article is published in Blood.The article was published on 2013-06-06 and is currently open access. It has received 178 citations till now. The article focuses on the topics: Lymphoma & CXCL13.read more
Citations
More filters
Journal ArticleDOI
Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.
TL;DR: A review of the most promising approaches for the diagnosis of primary central nervous system lymphoma can be found in this paper, where the authors discuss the potential procedural morbidity and mortality, as well as the time to definite histopathologic diagnosis resulting in delays of treatment initiation.
Journal ArticleDOI
High Level of IL-10 in Cerebrospinal Fluid is Specific for Diagnosis of Primary Central Nervous System Lymphoma
TL;DR: The CSF level of IL-10 is a useful diagnostic biomarker in patients with PCNSL and the best combination was IL- 10 and IL-17A, whose sensitivity was 70% and specificity was 96%.
Journal ArticleDOI
Cerebrospinal fluid approach on neuro-oncology
TL;DR: New technologies such as flow cytometry, molecular genetics and newer biomarkers may improve diagnostic sensitivity and specificity, leading to the CNS involvement diagnosis, and consequently, to an effective prophylaxis and successful treatment.
Journal ArticleDOI
Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors
Severa Bunda,Jeffrey Zuccato,Mathew Voisin,Justin Z. Wang,Farshad Nassiri,Vikas Patil,Sheila Mansouri,Gelareh Zadeh +7 more
TL;DR: In this article, a review of the application of liquid biopsies for diagnosis and monitoring of central nervous system malignancies is presented, which mainly includes circulating tumor cells (CTC), circulating tumor nucleic acids (ctDNA, miRNA), exosomes and samples can be obtained from the cerebrospinal fluid, plasma and serum of patients with CNS malignancy.
Journal ArticleDOI
Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma.
Jing Liu,Yaming Wang,Xuefei Sun,Nan Ji,Shengjun Sun,Yajie Wang,Fusheng Liu,Qu Cui,Chen Wang,Yuanbo Liu +9 more
TL;DR: It is demonstrated that epigenetic alterations in the promoter region downregulated SHP1 expression in PCNSL patients andTherapeutical regimens with epigenetic modifiers may be a potential option for patients with PC NSL.
References
More filters
Journal ArticleDOI
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.
Mark H. Zweig,Gregory Campbell +1 more
TL;DR: Receiver-operating characteristic (ROC) plots provide a pure index of accuracy by demonstrating the limits of a test's ability to discriminate between alternative states of health over the complete spectrum of operating conditions.
Journal ArticleDOI
Basic principles of ROC analysis
TL;DR: ROC analysis is shown to be related in a direct and natural way to cost/benefit analysis of diagnostic decision making and the concepts of "average diagnostic cost" and "average net benefit" are developed and used to identify the optimal compromise among various kinds of diagnostic error.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation
Yoji Hayashita,Hirotaka Osada,Yoshio Tatematsu,Hideki Yamada,Kiyoshi Yanagisawa,Shuta Tomida,Yasushi Yatabe,Katsunobu Kawahara,Yoshitaka Sekido,Takashi Takahashi +9 more
TL;DR: Findings clearly suggest that marked overexpression of the miR-17-92 cluster with occasional gene amplification may play a role in the development of lung cancers, especially in their most aggressive form, small-cell lung cancer, and that the C13orf25 gene may well be serving as a vehicle in this regard.
Journal ArticleDOI
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more
TL;DR: An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
Related Papers (5)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J.M. Ferreri,Michele Reni,Marco Foppoli,Maurizio Martelli,Gerasimus A. Pangalis,Maurizio Frezzato,Maria Giuseppina Cabras,Alberto Fabbri,Gaetano Corazzelli,Fiorella Ilariucci,Giuseppe Rossi,Riccardo Soffietti,Caterina Stelitano,Daniele Vallisa,Francesco Zaja,Lucia Zoppegno,Gian Marco Aondio,Giuseppe Avvisati,Monica Balzarotti,Alba A. Brandes,José Luis Crespo Fajardo,Henry L. Gomez,Attilio Guarini,Graziella Pinotti,Luigi Rigacci,Catrina Uhlmann,Piero Picozzi,Paolo Vezzulli,Maurilio Ponzoni,Emanuele Zucca,Federico Caligaris-Cappio,Franco Cavalli +31 more
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more